The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia

Atherosclerosis. 1973 Nov-Dec;18(3):353-62. doi: 10.1016/0021-9150(73)90065-8.
No abstract available

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Anticholesteremic Agents / pharmacology*
  • Blood Protein Disorders / complications
  • Cholesterol / blood
  • Clinical Trials as Topic
  • Creatinine / blood
  • Female
  • Glycolates / pharmacology*
  • Gout / metabolism*
  • Halofenate / administration & dosage
  • Halofenate / pharmacology
  • Humans
  • Hyperlipidemias / complications
  • Hyperlipidemias / drug therapy*
  • Hyperlipidemias / metabolism
  • Hypolipidemic Agents / pharmacology*
  • Lipoproteins / blood
  • Liver Function Tests
  • Male
  • Middle Aged
  • Placebos
  • Triglycerides / blood
  • Uric Acid / blood*
  • Uric Acid / urine*

Substances

  • Anticholesteremic Agents
  • Glycolates
  • Hypolipidemic Agents
  • Lipoproteins
  • Placebos
  • Triglycerides
  • Uric Acid
  • Cholesterol
  • Creatinine
  • Halofenate